Though not entirely specific, the mutation has been identified in 95% to 97% of patients with LPL compared to only 7% of patients with MZL, with a higher prevalence in MZL patients that are not class-switched to IgM+.4 Here, CD40LG is linked to marginal zone lymphoma.